Anti-cytomegalovirus preemptive therapy to prevent cytomegalovirus disease in HIV-infected patients: a systematic review.
Prenali Dwisthi SattwikaYanri Wijayanti SubrontoHeni RetnowulanKarina Ambar SattwikaDetty Siti NurdiatiPublished in: Infectious diseases (London, England) (2023)
With the advent of HAART, a limited number of studies have been performed to explore anti-CMV preemptive therapy due to the improved outcomes of HIV patients with CMV viremia. Therefore, optimal HAART should take precedence over anti-CMV preemptive therapy. The protocol for this review was registered in the Prospective Register of Systematic Reviews (CRD42020145765).
Keyphrases
- hiv infected patients
- antiretroviral therapy
- hiv infected
- epstein barr virus
- randomized controlled trial
- hiv positive
- human immunodeficiency virus
- hepatitis c virus
- type diabetes
- hiv testing
- skeletal muscle
- diffuse large b cell lymphoma
- bone marrow
- men who have sex with men
- cell therapy
- insulin resistance
- smoking cessation